|
[1]POLSON J, LEE WM.AASLD position paper:The management of acute liver failure[J].Hepatology, 2005, 41 (5) :1179-1197.
|
|
[2]Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association;Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association.Diagnostic and treatment guidelines for liver failure[J].Inter J Epidemiol Infect Dis, 2006, 33 (4) :217-221. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J].国际流行病学传染病学杂志, 2006, 33 (4) :217-221.
|
|
[3] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, CMA;Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, CMA.Guideline for diagnosis and treatment of liver failure[J].Chin J Clin Infect Dis, 2012, 5 (6) :321-327. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南 (2012年版) [J].中华临床感染病杂志, 2012, 5 (6) :321-327.
|
|
[4]SARIN SK, KEDARISETTY CK, ABBAS Z, et al.Acute-onchronic liver failure:Consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014[J].Hepatol Int, 2014, 8 (4) :453-471.
|
|
[5]European Association for the Study of the Liver.EASL clinical practical guidelines on the management of acute (fulminant) liver failure[J].J Hepatol, 2017, 66 (5) :1047-1081.
|
|
[6]FLAMM SL, YANG YX, SINGH S, et al.American gastroenterological association institute guidelines for the diagnosis and management of acute liver failure[J].Gastroenterology, 2017, 152 (3) :644-647.
|
|
[7]WU T, LI J, SHAO L, et al.Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-onchronic liver failure[J].Gut, 2018, 67 (12) :2181-2191.
|
|
[8]JALAN R, YURDAYDIN C, BAJAJ JS, et al.Toward an improved definition of acute-on-chronic liver failure[J].Gastroenterology, 2014, 147 (1) :4-10.
|
|
[9]ZHANG Q, LI Y, HAN T, et al.Comparison of current diagnostic criteria for acute-on-chronic liver failure[J/OL].PLo S One, 2015, 10 (3) :e0122158.
|
|
[10]European Association for the Study of the Liver.EASL Clinical Practice Guidelines on nutrition in chronic liver disease[J].JHepatol, 2019, 70 (1) :172-193.
|
|
[11]CHEN Y, YANG F, LU H, et al.Characterization of fecal microbial communities in patients with liver cirrhosis[J].Hepatology, 2011, 54 (2) :562-572.
|
|
[12]TILG H, CANI PD, MAYER EA.Gut microbiome and liver diseases[J].Gut, 2016, 65 (12) :2035-2044.
|
|
[13]PETROF EO, KHORUTS A.From stool transplants to nextgeneration microbiota therapeutics[J].Gastroenterology, 2014, 146 (6) :1573-1582.
|
|
[14]ROCKEY DC, SEEFF LB, ROCHON J, et al.Causality assessment in drug-induced liver injury using a structured expert opinion process:Comparison to the Roussel-Uclaf causality assessment method[J].Hepatology, 2010, 51 (6) :2117-2126.
|
|
[15]JINDAL A, KUMAR M, SARIN SK.Management of acute hepatitis B and reactivation of hepatitis B[J].Liver Int, 2013, 33 (Suppl 1) :164-175.
|
|
[16]SUN LJ, YU JW, ZHAO YH, et al.Influential factors of prognosis in lamivudine treatment for patients with acute-onchronic hepatitis B liver failure[J].J Gastroenterol Hepatol, 2010, 25 (3) :583-590.
|
|
[17]European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2018[J].J Hepatol, 2018, 69 (2) :461-511.
|
|
[18]SMILKSTEIN MJ, KNAPP GL, KULIG KW, et al.Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose.Analysis of the national multicenter study (1976 to1985) [J].N Engl J Med, 1988, 319 (24) :1557-1562.
|
|
[19]KEAYS R, HARRISON PM, WENDON JA, et al.Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure:A prospective controlled trial[J].BMJ, 1991, 303 (6809) :1026-1029.
|
|
[20]LEE WM, HYNAN LS, ROSSARO L, et al.Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure[J].Gastroenterology, 2009, 137 (3) :856-864.
|
|
[21]HRUBY K, CSOMOS G, FUHRMANN M, et al.Chemotherapy of amanita phalloides poisoning with intravenous silibinin[J].Hum Toxicol, 1983, 2 (2) :183-195.
|
|
[22]BROUSSARD CN, AGGARWAL A, LACEY SR, et al.Mushroom poisoning-from diarrhea to liver transplantation[J].Am J Gastroenterol, 2001, 96 (11) :3195-3198.
|
|
[23]ENJALBERT F, RAPIOR S, NOUGUIER-SOULJ, et al.Treatment of amatoxin poisoning:20-year retrospective analysis[J].J Toxicol Clin Toxicol, 2002, 40 (6) :715-757.
|
|
[24]CANALESE J, GIMSON AE, DAVIS C, et al.Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure[J].Gut, 1982, 23 (7) :625-629.
|
|
[25]KLINCK J, MCNEILL L, di ANGELANTONIO E, et al.Predictors and outcome impact of perioperative serum sodium changes in a high-risk population[J].Br J Anaesth, 2015, 114 (4) :615-622.
|
|
[26]JALAN R, OLDE DAMINK SW, DEUTZ NE, et al.Restoration of cerebral blood flow autoregulation and reactivity to carbon dioxide in acute liver failure by moderate hypothermia[J].Hepatology, 2001, 34 (1) :50-54.
|
|
[27]JALAN R, O DAMINK SW, DEUTZ NE, et al.Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure[J].Lancet, 1999, 354 (9185) :1164-1168.
|
|
[28]TOFTENG F, LARSEN FS.The effect of indomethacin on intracranial pressure, cerebral perfusion and extracellular lactate and glutamate concentrations in patients with fulminant hepatic failure[J].J Cereb Blood Flow Metab, 2004, 24 (7) :798-804.
|
|
[29]Chinese Society of Hepatology, Chinese Medical Association.Guidelines on the management of hepatic encephalopathy in cirrhosis[J].J Clin Hepatol, 2018, 34 (10) :2076-2089. (in Chinese) 中华医学会肝病学分会.肝硬化肝性脑病诊疗指南[J].临床肝胆病杂志, 2018, 34 (10) :2076-2089.
|
|
[30]VILSTRUP H, AMODIO P, BAJAJ J, et al.Hepatic encephalopathy in chronic liver disease:2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver[J].Hepatology, 2014, 60 (2) :715-735.
|
|
[31]GLUUD LL, VILSTRUP H, MORGAN MY.Nonabsorbable disaccharides for hepatic encephalopathy:A systematic review and meta-analysis[J].Hepatology, 2016, 64 (3) :908-922.
|
|
[32]GLUUD LL, VILSTRUP H, MORGAN MY.Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis[J].Cochrane Database Syst Rev, 2016, (5) :CD003044.
|
|
[33]BAI M, YANG Z, QI X, et al.L-ornithine-L-aspartate for hepatic encephalopathy in patients with cirrhosis:A meta-analysis of randomized controlled trials[J].J Gastroenterol Hepatol, 2013, 28 (5) :783-792.
|
|
[34]GLUUD LL, DAM G, LES I, et al.Branched-chain amino acids for people with hepatic encephalopathy[J].Cochrane Database Syst Rev, 2017, 5:CD001939.
|
|
[35]LACCETTI M, MANES G, UOMO G, et al.Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients:A double blind randomized placebo controlled study[J].Dig Liver Dis, 2000, 32 (4) :335-338.
|
|
[36]HANISH SI, STEIN DM, SCALEA JR, et al.Molecular adsorbent recirculating system effectively replaces hepatic function in severe acute liver failure[J].Ann Surg, 2017, 266 (4) :677-684.
|
|
[37]SALIBA F, CAMUS C, DURAND F, et al.Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure:A randomized, controlled trial[J].Ann Intern Med, 2013, 159 (8) :522-531.
|
|
[38]ROLANDO N, PHILPOTT-HOWARD J, WILLIAMS R.Bacterial and fungal infection in acute liver failure[J].Semin Liver Dis, 1996, 16 (4) :389-402.
|
|
[39]SILVESTRE JP, COELHO LM, PVOA PM.Impact of fulminant hepatic failure in C-reactive protein?[J].J Crit Care, 2010, 25 (4) :657.e7-e12.
|
|
[40]RULE JA, HYNAN LS, ATTAR N, et al.Procalcitonin identifies cell injury, not bacterial infection, in acute liver failure[J/OL].PLo S One, 2015, 10 (9) :e0138566.
|
|
[41]KARVELLAS CJ, CAVAZOS J, BATTENHOUSE H, et al.Effects of antimicrobial prophylaxis and blood stream infections in patients with acute liver failure:A retrospective cohort study[J].Clin Gastroenterol Hepatol, 2014, 12 (11) :1942-1949.e1.
|
|
[42]BERNAL W, AUZINGER G, DHAWAN A, et al.Acute liver failure[J].Lancet, 2010, 376 (9736) :190-201.
|
|
[43]FARMAKIOTIS D, KONTOYIANNIS DP.Emerging issues with diagnosis and management of fungal infections in solid organ transplant recipients[J].Am J Transplant, 2015, 15 (5) :1141-1147.
|
|
[44]UOJIMA H, KINBARA T, HIDAKA H, et al.Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites[J].Hepatol Res, 2017, 47 (3) :e14-e21.
|
|
[45]YAN L, XIE F, LU J, et al.The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites:A meta-analysis of randomized controlled trials[J].BMC Gastroenterol, 2015, 15:65.
|
|
[46]European Association for the Study of the Liver.EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J].J Hepatol, 2018, 69 (2) :406-460.
|
|
[47]MINDIKOGLU AL, PAPPAS SC.New developments in hepatorenal syndrome[J].Clin Gastroenterol Hepatol, 2018, 16 (2) :162-177.e1.
|
|
[48]SELBY NM, KUBBA AK, HAWKEY CJ.Acid suppression in peptic ulcer haemorrhage:A'meta-analysis'[J].Aliment Pharmacol Ther, 2000, 14 (9) :1119-1126.
|
|
[49]LEONTIADIS GI, SHARMA VK, HOWDEN CW.Proton pump inhibitor therapy for peptic ulcer bleeding:Cochrane collaboration meta-analysis of randomized controlled trials[J].Mayo Clin Proc, 2007, 82 (3) :286-296.
|
|
[50]IOANNOU G, DOUST J, ROCKEY DC.Terlipressin for acute esophageal variceal hemorrhage[J].Cochrane Database Syst Rev, 2003 (1) :CD002147.
|
|
[51]IMPERIALE TF, TERAN JC, MCCULLOUGH AJ.A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage[J].Gastroenterology, 1995, 109 (4) :1289-1294.
|
|
[52]LAINE L, COOK D.Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding.A meta-analysis[J].Ann Intern Med, 1995, 123 (4) :280-287.
|
|
[53]LIN LL, DU SM, FU Y, et al.Combination therapy versus pharmacotherapy, endoscopic variceal ligation, or the transjugular intrahepatic portosystemic shunt alone in the secondary prevention of esophageal variceal bleeding:A meta-analysis of randomized controlled trials[J].Oncotarget, 2017, 8 (34) :57399-57408.
|
|
[54]PEREIRA SP, ROWBOTHAM D, FITT S, et al.Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease[J].J Hepatol, 2005, 42 (3) :365-370.
|
|
[55] Liver Failure and Artificial Liver Group, Branch of Infectious Diseases, Chinese Medical Association.Guideline for non-bioartificial liver support systems in treatment of liver failure:2016 update[J].Chin J Clin Infect Dis, 2016, 9 (2) :97-103. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组.非生物型人工肝治疗肝衰竭指南 (2016年版) [J].中华临床感染病杂志, 2016, 9 (2) :97-103.
|
|
[56]STEADMAN RH, van RENSBURG A, KRAMER DJ.Transplantation for acute liver failure:Perioperative management[J].Curr Opin Organ Transplant, 2010, 15 (3) :368-373.
|
|
[57]LING Q, XU X, WEI Q, et al.Downgrading MELD improves the outcomes after liver transplantation in patients with acuteon-chronic hepatitis B liver failure[J/OL].PLo S One, 2012, 7 (1) :e30322.
|
|
[58]MOCHIDA S.Indication criteria for liver transplantation for acute liver failure in Japan[J].Hepatol Res, 2008, 38 (Suppl1) :s52-s55.
|
|
[59]RAO HY, GUO F, WEI L.Introduction and comments on AASLDpractice guidelines:Diagnosis and treatment of acute liver failure and assessment of liver transplant patients[J].Chin J Hepatol, 2006, 14 (2) :154-156. (in Chinese) 饶慧瑛, 郭芳, 魏来.2005年美国肝病学会急性肝衰竭诊治和肝移植患者评价指南简介[J].中华肝脏病杂志, 2006, 14 (2) :154-156.
|
|
[60]ARROYO V, MOREAU R, KAMATH PS, et al.Acute-onchronic liver failure in cirrhosis[J].Nat Rev Dis Primers, 2016, 2:16041.
|
|
[61]LINECKER M, KRONES T, BERG T, et al.Potentially inappropriate liver transplantation in the era of the"sickest first"policy-A search for the upper limits[J].J Hepatol, 2017.[Epub ahead of print]
|
DownLoad: